Literature DB >> 12200634

Lentiviral vectors for delivery of genes into neonatal and adult ventricular cardiac myocytes in vitro and in vivo.

Jing Zhao1, Gavin J Pettigrew, Joan Thomas, Jamie I Vandenberg, Luc Delriviere, Eleanor M Bolton, Andrew Carmichael, Jody L Martin, Michael S Marber, Andrew M L Lever.   

Abstract

Vectors based on lentiviruses such as human immunodeficiency virus (HIV) type-1 have many advantages for gene therapy, including the ability to infect non-dividing cells, long-term transgene expression and the absence of induction of an inflammatory/immune response. This study was initiated to determine whether lentiviruses would efficiently transfer genes to both neonatal and adult cardiac cells in culture and, by direct injection, to the heart in vivo. A three-plasmid expression system, including a packaging defective helper construct, a plasmid coding for a heterologous (VSV-G) envelope protein and a vector construct harboring reporter genes - E-GFP (enhanced green fluorescent protein) and puro (puromycin-resistance protein) was used to generate pseudotyped HIV-1 particles by transient transfection of human embryonic kidney 293T cells. We demonstrated efficient gene transfer into neonatal and adult cardiac myocytes in vitro and identified conditions in which virtually 100 % of cultured neonatal and 70 % of adult cardiac myocytes express the reporter gene. Transduction of adult cardiac myocytes with high titre lentiviral vectors did not affect the cell number, morphology or viability compared to untransduced cells. We delivered HIV-1-based vectors to the intact heart by direct injection. Hearts transduced with pseudotyped HIV-1 vectors showed levels of transgene expression comparable to that achieved by adenovirus vectors. This study demonstrates for the first time that lentivirus-based vectors can successfully transduce adult cardiomyocytes both in vitro and in vivo, and opens up the prospect of lentivirus-based vectors becoming an important gene delivery system in the cardiovascular field.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12200634     DOI: 10.1007/s00395-002-0360-0

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  25 in total

Review 1.  The evolution of heart gene delivery vectors.

Authors:  Nalinda B Wasala; Jin-Hong Shin; Dongsheng Duan
Journal:  J Gene Med       Date:  2011-10       Impact factor: 4.565

2.  Dual-reporter Imaging and its Potential Application in Tracking Studies.

Authors:  Jie Ding; Chao Wang; Pei-Cheng Li; Zhen Zhao; Cheng Qian; Cong-Xiao Wang; Yu Cai; Gao-Jun Teng
Journal:  J Fluoresc       Date:  2016-01       Impact factor: 2.217

Review 3.  Gene therapy to create biological pacemakers.

Authors:  Gerard J J Boink; Jurgen Seppen; Jacques M T de Bakker; Hanno L Tan
Journal:  Med Biol Eng Comput       Date:  2006-10-18       Impact factor: 2.602

Review 4.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

Review 5.  Methods in cardiomyocyte isolation, culture, and gene transfer.

Authors:  William E Louch; Katherine A Sheehan; Beata M Wolska
Journal:  J Mol Cell Cardiol       Date:  2011-06-24       Impact factor: 5.000

6.  Live cell imaging of primary rat neonatal cardiomyocytes following adenoviral and lentiviral transduction using confocal spinning disk microscopy.

Authors:  Takashi Sakurai; Anthony Lanahan; Melissa J Woolls; Na Li; Daniela Tirziu; Masahiro Murakami
Journal:  J Vis Exp       Date:  2014-06-24       Impact factor: 1.355

Review 7.  Site-specific gene therapy for cardiovascular disease.

Authors:  Ilia Fishbein; Michael Chorny; Robert J Levy
Journal:  Curr Opin Drug Discov Devel       Date:  2010-03

Review 8.  Gene therapy to treat cardiac arrhythmias.

Authors:  Rossana Bongianino; Silvia G Priori
Journal:  Nat Rev Cardiol       Date:  2015-04-28       Impact factor: 32.419

9.  Synergistic induction of miR-126 by hypoxia and HDAC inhibitors in cardiac myocytes.

Authors:  Huaping Shi; Lei Chen; Huilan Wang; Shoukang Zhu; Chunming Dong; Keith A Webster; Jianqin Wei
Journal:  Biochem Biophys Res Commun       Date:  2012-11-29       Impact factor: 3.575

10.  Refinement of lentiviral vector for improved RNA processing and reduced rates of self inactivation repair.

Authors:  Rachel M Koldej; Donald S Anson
Journal:  BMC Biotechnol       Date:  2009-10-07       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.